F M Snoeijen-Schouwenaars1, M J B M Veendrick2, P van Mierlo3, G van Erp3, A J A de Louw3, B U Kleine3, H J Schelhaas3, I Y Tan2. 1. Department of Residential Care, Kempenhaeghe, The Netherlands. Electronic address: SchouwenaarsF@kempenhaeghe.nl. 2. Department of Residential Care, Kempenhaeghe, The Netherlands. 3. Department of Neurology, Academic Center for Epileptology Kempenhaeghe/Maastricht University Medical Center, The Netherlands.
Abstract
PURPOSE: In newly diagnosed patients with Dravet syndrome sodium channel blockers are usually avoided. However, in many adult patients the diagnosis was made long after the initiation of therapy. The purpose of our study was to acquire information concerning the potential risks and benefits of (ox)carba(ma)zepine withdrawal in adult patients with genetically confirmed Dravet syndrome. METHOD: We identified 16 adults with Dravet syndrome, living in a tertiary care facility for people with epilepsy and an intellectual disability. We reviewed clinical history, genetic findings, the type and duration of sodium channels blockers that were used, seizure types and frequency, and the effect of a change in these medications. RESULTS: The study population consisted of 9 men and 7 women. Median age was 35 years (range 20-61 years). An attempt to withdraw carbamazepine (CBZ) was made in 9 patients. In 3 of these patients an increase in tonic-clonic seizures was observed. An attempt to withdraw oxcarbazepine (OXC) was made in 3 patients, leading to a complete stop in 2 patients. 3 of the 4 deaths in the withdrawal-group were related to epilepsy. CONCLUSION: In adult patients with Dravet syndrome withdrawal of CBZ or OXC is not without risks. We suggest that (ox)carba(ma)zepine withdrawal should be considered in these patients but only if there is a good reason to do so and only if they are closely monitored.
PURPOSE: In newly diagnosed patients with Dravet syndrome sodium channel blockers are usually avoided. However, in many adult patients the diagnosis was made long after the initiation of therapy. The purpose of our study was to acquire information concerning the potential risks and benefits of (ox)carba(ma)zepine withdrawal in adult patients with genetically confirmed Dravet syndrome. METHOD: We identified 16 adults with Dravet syndrome, living in a tertiary care facility for people with epilepsy and an intellectual disability. We reviewed clinical history, genetic findings, the type and duration of sodium channels blockers that were used, seizure types and frequency, and the effect of a change in these medications. RESULTS: The study population consisted of 9 men and 7 women. Median age was 35 years (range 20-61 years). An attempt to withdraw carbamazepine (CBZ) was made in 9 patients. In 3 of these patients an increase in tonic-clonic seizures was observed. An attempt to withdraw oxcarbazepine (OXC) was made in 3 patients, leading to a complete stop in 2 patients. 3 of the 4 deaths in the withdrawal-group were related to epilepsy. CONCLUSION: In adult patients with Dravet syndrome withdrawal of CBZ or OXC is not without risks. We suggest that (ox)carba(ma)zepine withdrawal should be considered in these patients but only if there is a good reason to do so and only if they are closely monitored.
Authors: Ana Carla Mondek Rampazzo; Rafael Rodrigues Pinheiro Dos Santos; Fernando Arfux Maluf; Renata Faria Simm; Fernando Augusto Lima Marson; Manoela Marques Ortega; Paulo Henrique Pires de Aguiar Journal: Neurogenetics Date: 2021-05-03 Impact factor: 2.660
Authors: Aliesha Griffin; Kyla R Hamling; SoonGweon Hong; Mana Anvar; Luke P Lee; Scott C Baraban Journal: Front Pharmacol Date: 2018-06-04 Impact factor: 5.810
Authors: Laura B Jones; Colin H Peters; Richard E Rosch; Maxine Owers; Elaine Hughes; Deb K Pal; Peter C Ruben Journal: Front Pharmacol Date: 2021-12-02 Impact factor: 5.810